Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Naltrexone depot (DrugAbuse Sciences).

Vania Modesto-Lowe1

  • 1Alcohol Research Center, Department of Psychiatry, University of Connecticut Health Center, Farmington, CT 06030, USA. modesto@psychiatry.uchc.edu

Idrugs : the Investigational Drugs Journal
|June 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Balancing Relief and Risk: Managing Chronic Low Back Pain in Patients with Opioid Use Disorder.

Southern medical journal·2026
Same author

Preparing for Care: A Clinician's Perspective on Anticipatory Caregiving and Meaning Making.

Journal of participatory medicine·2026
Same author

Psychosis and Kratom: Rare but Real?

The primary care companion for CNS disorders·2026
Same author

Semaglutide for Alcohol Use Disorder.

The primary care companion for CNS disorders·2026
Same author

Complicated Grief: Is There a Role for Naltrexone?

The primary care companion for CNS disorders·2025
Same author

Toward Consensus in Psychedelic-Assisted Therapy: The Critical Role of Psychotherapeutic Support.

The Journal of clinical psychiatry·2025

DrugAbuse Sciences is developing naltrexone depot, a sustained-release injectable formulation. This aims to improve compliance for alcoholism and opiate addiction treatment compared to daily oral naltrexone.

Area of Science:

  • Addiction medicine
  • Pharmacology

Background:

  • Naltrexone is an opioid antagonist used to treat alcoholism and opiate addiction.
  • Daily oral naltrexone formulations suffer from poor patient compliance.
  • A sustained-release injectable formulation could improve treatment adherence.

Purpose of the Study:

  • To develop and evaluate naltrexone depot, a sustained-release injectable formulation of naltrexone.
  • To assess the efficacy and safety of naltrexone depot for alcoholism and opiate addiction.

Main Methods:

  • Naltrexone depot is an injectable sustained-release (SR) formulation.
  • Phase III trials are evaluating naltrexone depot for alcoholism.
  • Phase II trials are evaluating naltrexone depot (Naltrel) for opiate addiction.

Related Experiment Videos

Main Results:

  • Ongoing trials are investigating the effectiveness of naltrexone depot.
  • The sustained-release formulation aims to address compliance issues.
  • Naltrexone depot is being studied in both alcoholic and opiate-addicted populations.

Conclusions:

  • Naltrexone depot offers a potential solution for improving treatment compliance in addiction.
  • Further clinical trials are necessary to confirm the efficacy and safety of this novel formulation.